Lipid Metabolism as a Potential Target of Liver Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Marengo A, Rosso C, Bugianesi E. Liver Cancer: connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med. 2016;67(1):103–117. doi:10.1146/annurev-med-090514-013832
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):2. doi:10.1016/j.cld.2011.03.006
   Web of Science ®Google Scholar
• EASL Clinical Practice. Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Llovet JM, Villanueva A, Marrero JA, et al. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology. 2021;73(Suppl 1):158–191. doi:10.1002/hep.31327
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-1007122
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology. 2013;57(4):1426–1435. doi:10.1002/hep.25832
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo B-Y, Hsu C-H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, Phase 1b study. Lancet Oncol. 2020;21(6):808–820. doi:10.1016/S1470-2045(20)30156-X
   PubMed Web of Science ®Google Scholar
• Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279(15):2610–2623. doi:10.1111/j.1742-4658.2012.08644.x
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–777. doi:10.1038/nrc2222
   PubMed Web of Science ®Google Scholar
• Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem. 2011;54(16):5615–5638. doi:10.1021/jm2005805
   PubMed Web of Science ®Google Scholar
• Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 2014;24(8):472–478. doi:10.1016/j.tcb.2014.06.001
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Marlow LA, Wei JJ, et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013;19(9):2368–2380. doi:10.1158/1078-0432.CCR-12-3249
   PubMed Web of Science ®Google Scholar
• Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40(5):1367–1393.
   PubMed Web of Science ®Google Scholar
• Luo X, Cheng C, Tan Z, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017;16(1):76.
   PubMed Web of Science ®Google Scholar
• Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52(4):585–589. doi:10.1016/j.plipres.2013.08.005
   PubMed Web of Science ®Google Scholar
• Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16(12):748–766.
   PubMed Web of Science ®Google Scholar
• Xu K, Xia P, Gongye X, et al. A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression. Mol Metabol. 2022;63:101540. doi:10.1016/j.molmet.2022.101540
   PubMed Web of Science ®Google Scholar
• Xu K, Xia P, Chen X, Ma W, Yuan Y. ncRNA-mediated fatty acid metabolism reprogramming in HCC. Trend Endocrinol Metabol. 2023;34(5):278–291. doi:10.1016/j.tem.2023.02.007
   PubMed Web of Science ®Google Scholar
• Xu K, Wu T, Xia P, Chen X, Yuan Y. Alternative splicing: a bridge connecting NAFLD and HCC. Trends Mol Med. 2023;29(10):859–872.
   PubMed Web of Science ®Google Scholar
• Xu K, Xia P, Liu P, Zhang X. A six lipid metabolism related gene signature for predicting the prognosis of hepatocellular carcinoma. Sci Rep. 2022;12(1):20781. doi:10.1038/s41598-022-25356-2
   PubMed Web of Science ®Google Scholar
• Muir K, Hazim A, He Y, et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 2013;73(15):4722–4731. doi:10.1158/0008-5472.CAN-12-3797
   PubMed Web of Science ®Google Scholar
• Nelson GM, Ahlborn GJ, Allen JW, et al. Transcriptional changes associated with reduced spontaneous liver tumor incidence in mice chronically exposed to high dose arsenic. Toxicology. 2009;266(1–3):1–3. doi:10.1016/j.tox.2009.10.004
   PubMed Web of Science ®Google Scholar
• Falvella FS, Pascale RM, Gariboldi M, et al. Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis. 2002;23(11):1933–1936. doi:10.1093/carcin/23.11.1933
   PubMed Web of Science ®Google Scholar
• Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218:1.
   Web of Science ®Google Scholar
• Matsushita Y, Nakagawa H, Koike K. Lipid Metabolism in Oncology: why It Matters, How to Research, and How to Treat. Cancers. 2021;13(3):3. doi:10.3390/cancers13030474
   Web of Science ®Google Scholar
• Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Theranostics. 2019;9(17):4893–4908. doi:10.7150/thno.36037
   PubMed Web of Science ®Google Scholar
• Yang X, Okamura DM, Lu X, et al. CD36 in chronic kidney disease: novel insights and therapeutic opportunities. Nat Rev Nephrol. 2017;13(12):769–781.
   PubMed Web of Science ®Google Scholar
• DeFilippis RA, Chang H, Dumont N, et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012;2(9):826–839. doi:10.1158/2159-8290.CD-12-0107
   PubMed Web of Science ®Google Scholar
• Yoshida T, Yokobori T, Saito H, et al. CD36 Expression Is Associated with Cancer Aggressiveness and Energy Source in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2021;28(2):1217–1227.
   PubMed Web of Science ®Google Scholar
• Wang J, Wen T, Li Z, et al. CD36 upregulates DEK transcription and promotes cell migration and invasion via GSK-3β/β-catenin-mediated epithelial-to-mesenchymal transition in gastric cancer. Aging. 2020;13(2):1883–1897. doi:10.18632/aging.103985
   PubMedGoogle Scholar
• Panda D, Chatterjee G, Sardana R, et al. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry B Clin Cytom. 2021;100(2):206–217. doi:10.1002/cyto.b.21943
   PubMed Web of Science ®Google Scholar
• Jia S, Zhou L, Shen T, Zhou S, Ding G, Cao L. Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis. J Cancer. 2018;9(3):578–583. doi:10.7150/jca.21046
   PubMed Web of Science ®Google Scholar
• Tao L, Ding X, Yan L, et al. CD36 accelerates the progression of hepatocellular carcinoma by promoting FAs absorption. Med Oncol. 2022;39(12):202. doi:10.1007/s12032-022-01808-7
   PubMed Web of Science ®Google Scholar
• Son N-H, Basu D, Samovski D, et al. Endothelial cell CD36 optimizes tissue fatty acid uptake. J Clin Invest. 2018;128(10):4329–4342. doi:10.1172/JCI99315
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–964. doi:10.1016/j.jhep.2011.08.025
   PubMed Web of Science ®Google Scholar
• Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005;24(41):6314–6322. doi:10.1038/sj.onc.1208773
   PubMed Web of Science ®Google Scholar
• Pope ED, Kimbrough EO, Vemireddy LP, Surapaneni PK, Copland JA, Mody K. Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opin Ther Targets. 2019;23(6):473–483. doi:10.1080/14728222.2019.1615883
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Kim HJ, Man WC, Ntambi JM. Oleoyl-CoA is the major de novo product of stearoyl-CoA desaturase 1 gene isoform and substrate for the biosynthesis of the Harderian gland 1-alkyl-2,3-diacylglycerol. J Biol Chem. 2001;276(42):39455–39461. doi:10.1074/jbc.M106442200
   PubMed Web of Science ®Google Scholar
• Yin X, Xu R, Song J, et al. Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Cancer Commun. 2022;42(12):1234–1256. doi:10.1002/cac2.12360
   Web of Science ®Google Scholar
• Bempedoic GP. Acid to Lower LDL Cholesterol - Safety and Efficacy. N Engl J Med. 2020;383(7):e49.
   PubMed Web of Science ®Google Scholar
• Chen Y, Qian J, He Q, et al. mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer. Oncotarget. 2016;7(18):25224–25240. doi:10.18632/oncotarget.8279
   PubMedGoogle Scholar
• Qian X, Hu J, Zhao J, Chen H. ATP citrate lyase expression is associated with advanced stage and prognosis in gastric adenocarcinoma. Int J Clin Exp Med. 2015;8(5):7855–7860.
   PubMed Web of Science ®Google Scholar
• Khwairakpam AD, Banik K, Girisa S, et al. The vital role of ATP citrate lyase in chronic diseases. J Mol Med. 2020;98(1):71–95. doi:10.1007/s00109-019-01863-0
   PubMed Web of Science ®Google Scholar
• Gu L, Zhu Y, Lin X, et al. The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis. Hepatology. 2021;73(1):160–174. doi:10.1002/hep.31249
   PubMed Web of Science ®Google Scholar
• Lligona-Trulla L, Arduini A, Aldaghlas TA, Calvani M, Kelleher JK. Acetyl-L-carnitine flux to lipids in cells estimated using isotopomer spectral analysis. J Lipid Res. 1997;38(7):1454–1462. doi:10.1016/S0022-2275(20)37427-7
   PubMed Web of Science ®Google Scholar
• Ning Z, Guo X, Liu X, et al. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma. Nat Commun. 2022;13(1):2187. doi:10.1038/s41467-022-29846-9
   PubMed Web of Science ®Google Scholar
• Schug ZT, Peck B, Jones DT, et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 2015;27(1):57–71. doi:10.1016/j.ccell.2014.12.002
   PubMed Web of Science ®Google Scholar
• Li X, Yu W, Qian X, et al. Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy. Mol Cell. 2017;66(5):5. doi:10.1016/j.molcel.2017.04.026
   PubMed Web of Science ®Google Scholar
• Li Z, Liu H, He J, et al. Acetyl-CoA Synthetase 2: a Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. Cell Metab. 2021;33(1):1. doi:10.1016/j.cmet.2020.12.011
   PubMed Web of Science ®Google Scholar
• Yun M, Bang S-H, Kim JW, Park JY, Kim KS, Lee JD. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med. 2009;50(8):1222–1228. doi:10.2967/jnumed.109.062703
   PubMed Web of Science ®Google Scholar
• Bidkhori G, Benfeitas R, Klevstig M, et al. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes. Proc Natl Acad Sci U S A. 2018;115(50):E11874–E11883. doi:10.1073/pnas.1807305115
   PubMed Web of Science ®Google Scholar
• Moffett JR, Puthillathu N, Vengilote R, Jaworski DM, Namboodiri AM. Acetate Revisited: a Key Biomolecule at the Nexus of Metabolism, Epigenetics and Oncogenesis-Part 1: acetyl-CoA, Acetogenesis and Acyl-CoA Short-Chain Synthetases. Front Physiol. 2020;11:580167. doi:10.3389/fphys.2020.580167
   PubMed Web of Science ®Google Scholar
• Moffett JR, Puthillathu N, Vengilote R, Jaworski DM, Namboodiri AM. Acetate Revisited: a Key Biomolecule at the Nexus of Metabolism, Epigenetics, and Oncogenesis - Part 2: acetate and ACSS2 in Health and Disease. Front Physiol. 2020;11:580171. doi:10.3389/fphys.2020.580171
   PubMed Web of Science ®Google Scholar
• Xu H, Luo J, Ma G, et al. Acyl-CoA synthetase short-chain family member 2 (ACSS2) is regulated by SREBP-1 and plays a role in fatty acid synthesis in caprine mammary epithelial cells. J Cell Physiol. 2018;233(2):1005–1016. doi:10.1002/jcp.25954
   PubMed Web of Science ®Google Scholar
• Sun L, Kong Y, Cao M, et al. Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Cancer Sci. 2017;108(7):1338–1346. doi:10.1111/cas.13252
   PubMed Web of Science ®Google Scholar
• Tong L. Structure and function of biotin-dependent carboxylases. Cell Mol Life Sci. 2013;70(5):863–891. doi:10.1007/s00018-012-1096-0
   PubMed Web of Science ®Google Scholar
• Hunkeler M, Hagmann A, Stuttfeld E, et al. Structural basis for regulation of human acetyl-CoA carboxylase. Nature. 2018;558(7710):470–474. doi:10.1038/s41586-018-0201-4
   PubMed Web of Science ®Google Scholar
• Chen L, Duan Y, Wei H, et al. Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors. Expert Opin Investig Drugs. 2019;28(10):917–930. doi:10.1080/13543784.2019.1657825
   PubMed Web of Science ®Google Scholar
• Rios Garcia M, Steinbauer B, Srivastava K, et al. Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence. Cell Metab. 2017;26(6):6. doi:10.1016/j.cmet.2017.09.018
   PubMed Web of Science ®Google Scholar
• Ueda K, Nakatsu Y, Yamamotoya T, et al. Prolyl isomerase Pin1 binds to and stabilizes acetyl CoA carboxylase 1 protein, thereby supporting cancer cell proliferation. Oncotarget. 2019;10(17):1637–1648. doi:10.18632/oncotarget.26691
   PubMedGoogle Scholar
• Fang W, Cui H, Yu D, Chen Y, Wang J, Yu G. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol. 2014;31(7):15. doi:10.1007/s12032-014-0015-7
   PubMed Web of Science ®Google Scholar
• Ghoshal S. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. Cell Metab. 2019;29(1):174–182.e5. doi:10.1016/j.cmet.2018.08.020
   PubMed Web of Science ®Google Scholar
• Yu X, Lin Q, Wu Z, et al. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p. J Pathol. 2020;252(4):358–370. doi:10.1002/path.5530
   PubMedGoogle Scholar
• Zhang Y, Xu J, Qiu Z, et al. STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway. Cancer Cell Int. 2022;22(1):4. doi:10.1186/s12935-021-02421-w
   PubMed Web of Science ®Google Scholar
• Li K, Zhang C, Chen L, et al. The role of acetyl-coA carboxylase2 in head and neck squamous cell carcinoma. PeerJ. 2019;7:e7037. doi:10.7717/peerj.7037
   PubMed Web of Science ®Google Scholar
• Banerjee P. Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2018;8(4):390–402. doi:10.1016/j.jceh.2018.04.001
   PubMedGoogle Scholar
• Rawson R. The SREBP pathway--insights from Insigs and insects. Nat Rev Mol Cell Biol. 2003;4(8):631–640. doi:10.1038/nrm1174
   PubMed Web of Science ®Google Scholar
• Wu D, Yang Y, Hou Y, et al. Increased mitochondrial fission drives the reprogramming of fatty acid metabolism in hepatocellular carcinoma cells through suppression of Sirtuin 1. Cancer Commun. 2022;42(1):37–55. doi:10.1002/cac2.12247
   Web of Science ®Google Scholar
• Li Y, Yang W, Zheng Y, et al. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res. 2023;42(1):6. doi:10.1186/s13046-022-02567-z
   PubMed Web of Science ®Google Scholar
• Gu L, Zhu Y, Lin X, Tan X, Lu B, Li Y. Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis. Oncogene. 2020;39(11):2437–2449. doi:10.1038/s41388-020-1156-0
   PubMed Web of Science ®Google Scholar
• Castro LFC, Wilson JM, Gonçalves O, Galante-Oliveira S, Rocha E, Cunha I. The evolutionary history of the stearoyl-CoA desaturase gene family in vertebrates. BMC Evol Biol. 2011;11:132. doi:10.1186/1471-2148-11-132
   PubMed Web of Science ®Google Scholar
• Wang J, Yu L, Schmidt RE, et al. Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates. Biochem Biophys Res Commun. 2005;332(3):735–742. doi:10.1016/j.bbrc.2005.05.013
   PubMed Web of Science ®Google Scholar
• Bené H, Lasky D, Ntambi JM. Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem Biophys Res Commun. 2001;284(5):1194–1198. doi:10.1006/bbrc.2001.5102
   PubMed Web of Science ®Google Scholar
• Carbone M, Melino G. Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives. Cancer Res. 2019;79(20):5149–5150. doi:10.1158/0008-5472.CAN-19-2453
   PubMed Web of Science ®Google Scholar
• Mkf M, Lau EYT, Leung DHW, et al. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J Hepatol. 2017;67(5):979–990. doi:10.1016/j.jhep.2017.06.015
   PubMed Web of Science ®Google Scholar
• Liu -H-H, Xu Y, C-J L, et al. An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming. Mol Ther. 2022;30(7):2554–2567. doi:10.1016/j.ymthe.2022.03.015
   PubMed Web of Science ®Google Scholar
• Li H, Chen Z, Zhang Y, et al. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett. 2021;519:161–171. doi:10.1016/j.canlet.2021.07.029
   PubMed Web of Science ®Google Scholar
• Lim GB. Inhibiting fatty acid oxidation promotes cardiomyocyte proliferation. Nat Rev Cardiol. 2020;17(5):266–267. doi:10.1038/s41569-020-0361-4
   PubMed Web of Science ®Google Scholar
• Houten SM, Violante S, Ventura FV, Wanders RJA. The Biochemistry and Physiology of Mitochondrial Fatty Acid β-Oxidation and Its Genetic Disorders. Annu Rev Physiol. 2016;78:23–44. doi:10.1146/annurev-physiol-021115-105045
   PubMed Web of Science ®Google Scholar
• Wang T, Fahrmann JF, Lee H, et al. JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab. 2018;27(1):136–150.e5. doi:10.1016/j.cmet.2017.11.001
   PubMed Web of Science ®Google Scholar
• Jiang N, Xie B, Xiao W, et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat Commun. 2022;13(1):1511. doi:10.1038/s41467-022-29137-3
   PubMed Web of Science ®Google Scholar
• Shi J, Fu H, Jia Z, He K, Fu L, Wang W. High Expression of CPT1A Predicts Adverse Outcomes: a Potential Therapeutic Target for Acute Myeloid Leukemia. EBioMedicine. 2016;14:55–64. doi:10.1016/j.ebiom.2016.11.025
   PubMed Web of Science ®Google Scholar
• Shao H, Mohamed EM, Xu GG, et al. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. 2016;7(4):3832–3846. doi:10.18632/oncotarget.6757
   PubMedGoogle Scholar
• Wu T, Luo G, Lian Q, et al. Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis. Hepatology. 2021;74(6):3249–3268. doi:10.1002/hep.32088
   PubMed Web of Science ®Google Scholar
• Senni N, Savall M, Cabrerizo Granados D, et al. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut. 2019;68(2):322–334. doi:10.1136/gutjnl-2017-315448
   PubMed Web of Science ®Google Scholar
• Zielinski ZAM, Pratt DA. Lipid Peroxidation: kinetics, Mechanisms, and Products. J Org Chem. 2017;82(6):2817–2825. doi:10.1021/acs.joc.7b00152
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042
   PubMed Web of Science ®Google Scholar
• Tang D, Kroemer G. Ferroptosis. Curr Biol. 2020;30(21):R1292–R1297. doi:10.1016/j.cub.2020.09.068
   PubMed Web of Science ®Google Scholar
• Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381–396. doi:10.1038/s41568-022-00459-0
   PubMed Web of Science ®Google Scholar
• Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146–162. doi:10.1038/s41422-019-0263-3
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhang Q, Sun X, et al. HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Res. 2017;77(8):2064–2077. doi:10.1158/0008-5472.CAN-16-1979
   PubMed Web of Science ®Google Scholar
• Yang M, Wu X, Hu J, et al. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. J Hepatol. 2022;76(5):1138–1150. doi:10.1016/j.jhep.2022.01.009
   PubMed Web of Science ®Google Scholar
• Chen Q, Zheng W, Guan J, et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2023;30(1):137–151. doi:10.1038/s41418-022-01051-7
   PubMed Web of Science ®Google Scholar
• Yao F, Deng Y, Zhao Y, et al. A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun. 2021;12(1):7333. doi:10.1038/s41467-021-27452-9
   PubMed Web of Science ®Google Scholar
• Gao R, Kalathur RKR, Coto-Llerena M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 2021;13(12):e14351. doi:10.15252/emmm.202114351
   PubMed Web of Science ®Google Scholar
• Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20(3):137–155. doi:10.1038/s41580-018-0085-z
   PubMed Web of Science ®Google Scholar
• Bacci M, Lorito N, Smiriglia A, Morandi A. Fat and Furious: lipid Metabolism in Antitumoral Therapy Response and Resistance. Trends Cancer. 2021;7(3):198–213. doi:10.1016/j.trecan.2020.10.004
   PubMed Web of Science ®Google Scholar
• Curtarello M, Tognon M, Venturoli C, et al. Rewiring of Lipid Metabolism and Storage in Ovarian Cancer Cells after Anti-VEGF Therapy. Cells. 2019;8(12):1601. doi:10.3390/cells8121601
   PubMed Web of Science ®Google Scholar
• Bensaad K, Favaro E, Lewis CA, et al. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014;9(1):349–365. doi:10.1016/j.celrep.2014.08.056
   PubMed Web of Science ®Google Scholar
• Berardi DE, Bock-Hughes A, Terry AR, Drake LE, Bozek G, Macleod KF. Lipid droplet turnover at the lysosome inhibits growth of hepatocellular carcinoma in a BNIP3-dependent manner. Sci Adv. 2022;8(41):eabo2510. doi:10.1126/sciadv.abo2510
   PubMed Web of Science ®Google Scholar
• Chen J, Ding C, Chen Y, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. Cancer Lett. 2021;502:154–165. doi:10.1016/j.canlet.2020.12.019
   PubMed Web of Science ®Google Scholar
• Pellerin L, Carrié L, Dufau C, et al. Lipid metabolic Reprogramming: role in Melanoma Progression and Therapeutic Perspectives. Cancers. 2020;12(11):3147. doi:10.3390/cancers12113147
   PubMed Web of Science ®Google Scholar
• Luo J, Yang H, Song B-L. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225–245.
   PubMed Web of Science ®Google Scholar
• Huang B, Song B-L, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132–141. doi:10.1038/s42255-020-0174-0
   PubMedGoogle Scholar
• Xu H, Zhou S, Tang Q, Xia H, Bi F. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188394. doi:10.1016/j.bbcan.2020.188394
   PubMed Web of Science ®Google Scholar
• Ma L, Wang L, Nelson AT, et al. 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression. Cancer Lett. 2020;493:266–283. doi:10.1016/j.canlet.2020.08.020
   PubMed Web of Science ®Google Scholar
• Garcia-Bermudez J, Baudrier L, Bayraktar EC, et al. Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. Nature. 2019;567(7746):118–122. doi:10.1038/s41586-019-0945-5
   PubMed Web of Science ®Google Scholar
• Guillaumond F, Bidaut G, Ouaissi M, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2015;112(8):2473–2478. doi:10.1073/pnas.1421601112
   PubMed Web of Science ®Google Scholar
• Qin W-H, Yang Z-S, Li M, et al. High Serum Levels of Cholesterol Increase Antitumor Functions of Nature Killer Cells and Reduce Growth of Liver Tumors in Mice. Gastroenterology. 2020;158(6):1713–1727. doi:10.1053/j.gastro.2020.01.028
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen L, Sun B, et al. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway. Mol Metab. 2021;51:101230. doi:10.1016/j.molmet.2021.101230
   PubMed Web of Science ®Google Scholar
• Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9(2):125–138. doi:10.1038/nrm2336
   PubMed Web of Science ®Google Scholar
• Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732–749. doi:10.1038/nrc.2016.89
   PubMed Web of Science ®Google Scholar
• Corn KC, Windham MA, Rafat M. Lipids in the tumor microenvironment: from cancer progression to treatment. Prog Lipid Res. 2020;80:101055. doi:10.1016/j.plipres.2020.101055
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Can Cell Inter. 2021;21(1):409. doi:10.1186/s12935-021-02108-2
   PubMed Web of Science ®Google Scholar
• Chang WC, Cheng WC, Cheng BH, et al. Mitochondrial Acetyl-CoA Synthetase 3 is Biosignature of Gastric Cancer Progression. Cancer Med. 2018;7(4):1240–1252. doi:10.1002/cam4.1295
   PubMed Web of Science ®Google Scholar
• Björnson E, Mukhopadhyay B, Asplund A, et al. Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization. Cell Rep. 2015;13(9):2014–2026. doi:10.1016/j.celrep.2015.10.045
   PubMed Web of Science ®Google Scholar
• Zhao Z, Lu J, Han L, Wang X, Man Q, Liu S. Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma. Tumour Biol. 2016;37(6):8121–8130. doi:10.1007/s13277-015-4720-4
   PubMedGoogle Scholar
• Mo H, Jeter R, Bachmann A, Yount ST, Shen C-L, Yeganehjoo H. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins. Front Pharmacol. 2018;9:1515. doi:10.3389/fphar.2018.01515
   PubMed Web of Science ®Google Scholar
• Chushi L, Wei W, Kangkang X, Yongzeng F, Ning X, Xiaolei C. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene. 2016;587(1):42–47. doi:10.1016/j.gene.2016.04.029
   PubMed Web of Science ®Google Scholar
• Sohda T, Iwata K, Hirano G, et al. 3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia. Med Mol Morphol. 2013;46(4):239–242. doi:10.1007/s00795-013-0042-z
   PubMed Web of Science ®Google Scholar
• Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–332. doi:10.1053/j.gastro.2012.10.005
   PubMed Web of Science ®Google Scholar
• Liang B, Chen R, Song S, et al. ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma. Cell Death Dis. 2019;10(11):830. doi:10.1038/s41419-019-2054-7
   PubMedGoogle Scholar
• Jun SY, Brown AJ, Chua NK, et al. Reduction of Squalene Epoxidase by Cholesterol Accumulation Accelerates Colorectal Cancer Progression and Metastasis. Gastroenterology. 2021;160(4):1194–1207.e28. doi:10.1053/j.gastro.2020.09.009
   PubMed Web of Science ®Google Scholar
• Li C, Wang Y, Liu D, et al. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut. 2022;71(11):2253–2265. doi:10.1136/gutjnl-2021-325851
   PubMed Web of Science ®Google Scholar
• You W, Ke J, Chen Y, et al. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma. Front Immunol. 2022;13:864244. doi:10.3389/fimmu.2022.864244
   PubMed Web of Science ®Google Scholar
• Kalogirou C, Linxweiler J, Schmucker P, et al. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 2021;12(1):5066. doi:10.1038/s41467-021-25325-9
   PubMed Web of Science ®Google Scholar
• Liu D, Wong CC, Fu L, et al. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. Sci Transl Med. 2018;10(437). doi:10.1126/scitranslmed.aap9840
   Web of Science ®Google Scholar
• Zhang E-B, Zhang X, Wang K, et al. Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene. 2021;40(34):5302–5313. doi:10.1038/s41388-021-01934-y
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu W, Jiao H, et al. Squalene epoxidase promotes hepatocellular carcinoma development by activating STRAP transcription and TGF-β/SMAD signalling. Br J Pharmacol. 2023;180(12):1562–1581. doi:10.1111/bph.16024
   PubMed Web of Science ®Google Scholar
• Oni TE, Biffi G, Baker LA, et al. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. J Exp Med. 2020;217(9). doi:10.1084/jem.20192389
   PubMed Web of Science ®Google Scholar
• Yue S, Li J, Lee S-Y, et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 2014;19(3):393–406. doi:10.1016/j.cmet.2014.01.019
   PubMed Web of Science ®Google Scholar
• Geng F, Cheng X, Wu X, et al. Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-Mediated Lipogenesis. Clin Cancer Res. 2016;22(21):5337–5348. doi:10.1158/1078-0432.CCR-15-2973
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang X, Chen Y, et al. Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma. BMC Cancer. 2021;21(1):615. doi:10.1186/s12885-021-08245-1
   PubMed Web of Science ®Google Scholar
• Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–261. doi:10.1038/s41586-019-0987-8
   PubMed Web of Science ®Google Scholar
• Zhu Y, Gu L, Lin X, et al. P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. Hepatology. 2023;77(5):1499–1511. doi:10.1002/hep.32518
   PubMed Web of Science ®Google Scholar
• Chang CC, Sakashita N, Ornvold K, et al. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem. 2000;275(36):28083–28092. doi:10.1074/jbc.M003927200
   PubMed Web of Science ®Google Scholar
• Huang Y, Jin Q, Su M, et al. Leptin promotes the migration and invasion of breast cancer cells by upregulating ACAT2. Cell Oncol Dordr. 2017;40(6):537–547. doi:10.1007/s13402-017-0342-8
   PubMed Web of Science ®Google Scholar
• Lu M, X-H H, Li Q, et al. A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. J Mol Cell Biol. 2013;5(6):404–415. doi:10.1093/jmcb/mjt039
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Subramanian S, Chait A, et al. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. J Lipid Res. 2017;58(6):1067–1079. doi:10.1194/jlr.M072454
   PubMed Web of Science ®Google Scholar
• Sharma B, Agnihotri N. Role of cholesterol homeostasis and its efflux pathways in cancer progression. J Steroid Biochem Mol Biol. 2019;191:105377. doi:10.1016/j.jsbmb.2019.105377
   PubMed Web of Science ®Google Scholar
• Delk SC, Chattopadhyay A, Escola-Gil JC, Fogelman AM, Reddy ST. Apolipoprotein mimetics in cancer. Semin Cancer Biol. 2021;73:158–168. doi:10.1016/j.semcancer.2020.11.002
   PubMed Web of Science ®Google Scholar
• Cao WM, Murao K, Imachi H, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004;64(4):1515–1521. doi:10.1158/0008-5472.CAN-03-0675
   PubMed Web of Science ®Google Scholar
• Schörghofer D, Kinslechner K, Preitschopf A, et al. The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen Independence. Reprod Biol Endocrinol. 2015;13:88. doi:10.1186/s12958-015-0087-z
   PubMed Web of Science ®Google Scholar
• Zheng Y, Liu Y, Jin H, et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics. 2013;3(7):477–486. doi:10.7150/thno.6617
   PubMed Web of Science ®Google Scholar
• Yuan B, Wu C, Wang X, et al. High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer. Tumour Biol. 2016;37(3):3581–3588. doi:10.1007/s13277-015-4141-4
   PubMedGoogle Scholar
• Schimanski S, Wild PJ, Treeck O, et al. Expression of the lipid transporters ABCA3 and ABCA1 is diminished in human breast cancer tissue. Horm Metab Res. 2010;42(2):102–109. doi:10.1055/s-0029-1241859
   PubMed Web of Science ®Google Scholar
• Smith B, Land H. Anticancer activity of the cholesterol exporter ABCA1 gene. Cell Rep. 2012;2(3):580–590. doi:10.1016/j.celrep.2012.08.011
   PubMed Web of Science ®Google Scholar
• Aguirre-Portolés C, Feliu J, Reglero G, Ramírez de Molina A. ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. Mol Oncol. 2018;12(10):1735–1752. doi:10.1002/1878-0261.12367
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu H, Ready NE, et al. Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients. Int J Cancer. 2016;138(11):2592–2601. doi:10.1002/ijc.29991
   PubMed Web of Science ®Google Scholar
• Demidenko R, Razanauskas D, Daniunaite K, Lazutka JR, Jankevicius F, Jarmalaite S. Frequent down-regulation of ABC transporter genes in prostate cancer. BMC Cancer. 2015;15:683. doi:10.1186/s12885-015-1689-8
   PubMed Web of Science ®Google Scholar
• Yuan J, Lv T, Yang J, et al. The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition. Cancer Lett. 2022;549:215921. doi:10.1016/j.canlet.2022.215921
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Xing R, et al. Cholesterol Efflux Drives the Generation of Immunosuppressive Macrophages to Promote the Progression of Human Hepatocellular Carcinoma. Cancer Immunol Res. 2023;11(10):1400–1413. doi:10.1158/2326-6066.CIR-22-0907
   PubMed Web of Science ®Google Scholar
• Liao X, Song G, Xu Z, et al. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. BMC Cancer. 2020;20(1):31. doi:10.1186/s12885-019-6480-9
   PubMed Web of Science ®Google Scholar
• Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710–730. doi:10.1038/nrendo.2017.91
   PubMed Web of Science ®Google Scholar
• Cheng L, Deepak RNVK, Wang G, et al. Hepatic mitochondrial NAD + transporter SLC25A47 activates AMPKα mediating lipid metabolism and tumorigenesis. Hepatology. 2023;78(6):1828–1842. doi:10.1097/HEP.0000000000000314
   PubMed Web of Science ®Google Scholar
• Tang W, Zhou J, Yang W, et al. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. 2022;19(7):834–847. doi:10.1038/s41423-022-00872-3
   PubMed Web of Science ®Google Scholar
• Mok EHK, Leung CON, Zhou L, et al. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma. Cancer Res. 2022;82(17):3102–3115. doi:10.1158/0008-5472.CAN-21-2934
   PubMed Web of Science ®Google Scholar
• Wang Y, Viscarra J, Kim S-J, Sul HS. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015;16(11):678–689. doi:10.1038/nrm4074
   PubMed Web of Science ®Google Scholar
• Rough JJ, Monroy MA, Yerrum S, Daly JM. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res. 2010;3:13. doi:10.1186/1757-2215-3-13
   PubMed Web of Science ®Google Scholar
• Srivastava S, Widmann S, Ho C, et al. Novel Liver X Receptor Ligand GAC0001E5 Disrupts Glutamine Metabolism and Induces Oxidative Stress in Pancreatic Cancer Cells. Int J Mol Sci. 2020;21(24):9622. doi:10.3390/ijms21249622
   PubMed Web of Science ®Google Scholar
• Yang B, Zhang B, Cao Z, et al. The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy. Cell Death Differ. 2020;27(8):2433–2450. doi:10.1038/s41418-020-0514-3
   PubMed Web of Science ®Google Scholar
• Rudalska R, Harbig J, Snaebjornsson MT, et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer. 2021;2(2):201–217. doi:10.1038/s43018-020-00168-3
   PubMedGoogle Scholar
• Lin Z, Xia S, Liang Y, et al. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Theranostics. 2020;10(19):8834–8850. doi:10.7150/thno.45158
   PubMed Web of Science ®Google Scholar
• Wagner N, Wagner KD. The Role of PPARs in Disease. Cells. 2020;9(11):2367. doi:10.3390/cells9112367
   PubMed Web of Science ®Google Scholar
• Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nuclear Receptor Signaling. 2010;8:e002. doi:10.1621/nrs.08002
   PubMedGoogle Scholar
• Blunder S, Pavel P, Minzaghi D, Dubrac S. PPARdelta in Affected Atopic Dermatitis and Psoriasis: a Possible Role in Metabolic Reprograming. Int J Mol Sci. 2021;22(14):7354. doi:10.3390/ijms22147354
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 2001;56:239–263. doi:10.1210/rp.56.1.239
   PubMedGoogle Scholar
• Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62(3):720–733. doi:10.1016/j.jhep.2014.10.039
   PubMed Web of Science ®Google Scholar
• Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. BBA. 2012;1821(5):809–818. doi:10.1016/j.bbalip.2011.10.016
   PubMed Web of Science ®Google Scholar
• Corton JC. Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites. Crit. Rev. Toxicol. 2008;38(10):857–875. doi:10.1080/10408440802209796
   PubMed Web of Science ®Google Scholar
• Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch. Toxicol. 2008;82(12):959–964. doi:10.1007/s00204-008-0312-z
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Matsuda T, Kobayashi S, Takahashi T, Kojima H. In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway. Toxicol Appl Pharmacol. 2006;217(3):235–244. doi:10.1016/j.taap.2006.08.011
   PubMed Web of Science ®Google Scholar
• Li J, Huang Q, Long X, et al. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways. J Hepatol. 2015;63(6):1378–1389.
   PubMed Web of Science ®Google Scholar
• Han W, Wang N, Kong R, Bao W, Lu J. Ligand-activated PPARδ expression promotes hepatocellular carcinoma progression by regulating the PI3K-AKT signaling pathway. J Transl Med. 2022;20(1):86. doi:10.1186/s12967-022-03288-9
   PubMed Web of Science ®Google Scholar
• Xiong Z, Chan SL, Zhou J, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72(9):1758–1773. doi:10.1136/gutjnl-2022-328364
   PubMed Web of Science ®Google Scholar
• Inc. SB. A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors; 2013. Available from: https://classic.clinicaltrials.gov/show/NCT02223247. Accessed January 2, 2024.
   Google Scholar
• Inc. SB. Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH); 2019. Available from: https://classic.clinicaltrials.gov/show/NCT03938246;. Accessed January 2, 2024.
   Google Scholar
• Inc. SB. Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH); 2019. Available from: https://classic.clinicaltrials.gov/show/NCT04906421.Accessed January 2, 2024.
   Google Scholar
• Center UoTSM. EGCG for Hepatocellular Carcinoma Chemoprevention; 2023. Available from: https://classic.clinicaltrials.gov/show/NCT06015022. Accessed January 2, 2024.
   Google Scholar
• Institute NC. Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis; 2017. Available from: https://classic.clinicaltrials.gov/show/NCT02968810. Accessed January 2, 2024.
   Google Scholar
• Chung R, Center Uo TSM, Hospital MG Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk; 2023. Available from: https://classic.clinicaltrials.gov/show/NCT05028829;. Accessed January 2, 2024.
   Google Scholar
• Hospital CC, Hospital E-D, Hospital NTU, et al. Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment; 2017. Available from: https://classic.clinicaltrials.gov/show/NCT03024684;. Accessed January 2, 2024.
   Google Scholar
• University Hospital G, Ghent U, Anticancer Fund B Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma; 2014. Available from: https://classic.clinicaltrials.gov/show/NCT02304289;.Accessed January 2, 2024.
   Google Scholar
• University OS. Xanthohumol and Prevention of DNA Damage; 2015. Available from: https://classic.clinicaltrials.gov/show/NCT02432651;. Accessed January 2, 2024.
   Google Scholar
• Antonio TUoTHSCaS. TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma; 2017. Availablr from: https://classic.clinicaltrials.gov/show/NCT03032484.Accessed January 2, 2024.
   Google Scholar
• Evers M, Institute NC, Kentucky U. TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial. 2017. Available from: https://classic.clinicaltrials.gov/show/NCT02980029;. Accessed January 2, 2024.
   Google Scholar
• Gerber DE, Sb I, Texas CPRIo, Center UoTSM. Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas; 2019. Available from: https://classic.clinicaltrials.gov/show/NCT03808558. Accessed January 02, 2024.
   Google Scholar
• University WMCoC, Inc. SB. Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer; 2023. Available from: https://classic.clinicaltrials.gov/show/NCT05743621.Accessed January 02, 2024.
   Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16(7):411–428. doi:10.1038/s41575-019-0145-7
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two Phase III studies. Clin Transl Oncol. 2019;21(6):810–816. doi:10.1007/s12094-018-1992-3
   PubMed Web of Science ®Google Scholar
• Miyata S, Inoue J, Shimizu M, Sato R. Xanthohumol Improves Diet-induced Obesity and Fatty Liver by Suppressing Sterol Regulatory Element-binding Protein (SREBP) Activation. J Biol Chem. 2015;290(33):20565–20579.
   PubMed Web of Science ®Google Scholar